Kiyohide Kioka

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 254 citations · Full text

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis

Hiromitsu Kumada, Kazuaki Chayama, Lino Rodrigues et al. · Hepatology · 2015 · 153 citations · Full text

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri et al. · The Lancet · 2025 · 151 citations · Full text

Hepatology, Transarterial Chemoembolisation, Medicine +8

Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients

Shinjiro Kobayashi, Tadashi Takeda, Masaru Enomoto et al. · Liver International · 2007 · 87 citations

Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct‐acting antiviral therapy

Akihiro Tamori, Seigo Abiru, Hirayuki Enomoto et al. · Journal of Viral Hepatitis · 2017 · 34 citations